Immediate-release tofacitinib reduces insulin resistance in non-diabetic active rheumatoid arthritis patients: A single-center retrospective study

Figure 2 Homeostatic model assessment-insulin resistance and Quantitative Insulin Sensitivity Check Index levels in 30 active rheumatoid arthritis patients naïve to biologic agents before and 24 wk after tofacitinib therapy. A: Homeostatic model assessment (HOMA)-insulin resistance (IR) levels in all 30 patients at weeks 0 and 24 after tofacitinib (TOF) therapy (P < 0.001); B: HOMA-IR levels in the high-IR group with 18 patients at weeks 0 and 24 after TOF therapy (P < 0.001); C: HOMA-IR levels in the low-IR group with 12 patients at weeks 0 and 24 after TOF therapy; D: Quantitative Insulin Sensitivity Check Index (QUICKI) levels in all 30 patients at weeks 0 and 24 after TOF therapy (P < 0.001); E: QUICKI levels in the high-IR group with 18 patients at weeks 0 and 24 after TOF therapy (P < 0.001); F: QUICKI levels in the low-IR group with 12 patients at weeks 0 and 24 after TOF therapy. QUICKI: Quantitative Insulin Sensitivity Check Index; HOMA-TR: Homeostatic model assessment-insulin resistance.